Stock Evaluator: Arvinas, Inc. (ARVN)

Arvinas, Inc. ARVN

$6.46 -0.28 -4.15%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 1,108,461
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Commentary & Analysis


Financial Summary

Share Statistics ARVN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $423.0 $421.5 37%
Shares Out (Mil) 65.4 46.9 53%
Institutional Ownership 97.3% 82.0% 73%
Float (Mil) 60.4 49.2 51%
Beta 1.80 0.68 89%
Avg Daily Volume (000s) 1,016 347 70%
Price Change
(52-week)
(44.0%) 49.3% 25%
Growth ARVN Industry
Median
Percentile
(All Stocks)
Sales (5yr) 58.9% 6.4% 97%
Net Income (5yr) 7.5% (1.3%) 51%
EPS (5yr) 17.7% 15.1% 64
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (47.2%) (15.0%) 8%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 11 11 12
Current EPS ($0.767) $0.159 ($3.177)
Month Ago EPS ($0.927) ($0.137) ($3.232)
# Rev Up 0 0 0
# Rev Down 1 1 2
Three Months Ago EPS ($0.885) ($0.068) ($3.072)
Year/Year Chg (6.9%) (113.9%) 140.1%
Financials ARVN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $275 $275 35%
Net Income (TTM) (Mil) ($10) ($11) 29%
EPS (TTM) ($0.147) ($0.700) 34%
Operating Cash Flow (TTM) (Mil) ($158) ($7) 4%
Net Cash Flow (TTM) (Mil) ($13) $1 31%
Long-Term Debt (Q1) (Mil) $6 $6 25%
Enterprise Value (Q1) (Mil) ($65) $331 1%
Valuation ARVN Industry
Median
Percentile
(All Stocks)
P/B 0.82 2.08 22%
P/E na 20.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios ARVN Industry
Median
Percentile
(All Stocks)
Gross Margin 96.7% 69.5% 96%
Net Margin (3.5%) 3.6% 26%
ROA (1.3%) (23.8%) 35%
ROE (1.8%) (24.2%) 33%
Liabilities to Assets 15.4% 31.6% 10%
F-Score 5 3 50%

Arvinas, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors